Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Project Updates and Milestones news
(page 2)
29 October 2025
Equinor Q3 2025 Financial Results
Adjusted operating income at $6.21B. Production up 7%. Strong cash flow, cost focus, and strategic developments. Dividend set at $0.37/share.
29 October 2025
OMV Boosts Q3 2025 Clean CCS Operating Result by 20% to EUR 1.3 Billion
Fuels and Chemicals drive growth; Energy segment declines. Cash flow up 7%, leverage at 16%. Progress on Borouge Group and Neptun Deep project.
29 October 2025
Neste Q3 2025 Interim Report
Improved Q3 results driven by performance actions and market recovery. Renewable and oil product sales rose, but cash flow was negative. Strategic growth in Rotterdam continues.
29 October 2025
BASF Q3 2025 Earnings Slightly Exceed Market Expectations
Sales fell 3% due to currency effects and lower prices. EBITDA before special items was €1.5 billion. Share buyback program to start in November 2025.
29 October 2025
Ørsted and Worley Sign Long-Term EPCM Agreement
The eight-year deal supports power generation and CCS in Denmark, enhancing energy infrastructure and decarbonization efforts with a focus on safety and sustainability.
28 October 2025
Aramco and GIP Finalize $11 Billion Jafurah Midstream Deal
The Jafurah project will start production by year-end, expanding gas capacity and supporting Saudi Arabia's growth in energy and petrochemicals.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
28 October 2025
Merck's KEYTRUDA and WELIREG Combo Improves DFS in RCC Patients Post-Nephrectomy
The LITESPARK-022 trial shows improved DFS with KEYTRUDA and WELIREG in RCC patients. Safety profiles align with previous studies. Results to be shared with regulators.
28 October 2025
Merck and Eisai's WELIREG and LENVIMA Improve PFS in Advanced Renal Cell Carcinoma Trial
The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
28 October 2025
Port of Rotterdam Throughput Declines 2.6% in Q3 2025
Throughput fell due to lower iron ore and mineral oil volumes. Container and renewable fuel throughput rose, highlighting the port's resilience amid European industry challenges.
28 October 2025
Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome
Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
27 October 2025
Dow's Freeport MDI Facility Achieves ISCC PLUS Certification
The Freeport facility now offers bio-circular isocyanates with ISCC PLUS certification, enhancing sustainability and supply chain transparency for various industries.
27 October 2025
Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
27 October 2025
Johnson & Johnson's Icotrokinra Shows Therapeutic Benefit and Safety in Ulcerative Colitis
Icotrokinra shows sustained clinical benefits and safety in ulcerative colitis, with Phase 3 trials underway for broader applications.
27 October 2025
Johnson & Johnson's TREMFYA® Shows Two-Year Remission in Crohn's Disease
TREMFYA® maintains remission in Crohn's disease over 96 weeks, with consistent safety and efficacy in both subcutaneous and intravenous regimens.
27 October 2025
RWE Plans Hydrogen-Ready Power Plant in Voerde
A new 850 MW hydrogen-compatible plant in Voerde aims to support Germany's energy transition, with construction starting post-tender approval and operation by 2030.
27 October 2025
Galp Q3 2025 Financial Results
Strong Q3 performance with robust cash flow, reduced net debt, and strategic progress in Brazil and Namibia. Upstream, Industrial, and Commercial segments showed solid results.
27 October 2025
Worley to Provide EPCm Services for Rio Tinto's BS1 Iron Ore Project
Worley will construct a primary crusher, conveyor, infrastructure, and camp for the BS1 project, extending Brockman's life and processing 34 Mtpa of iron ore by 2027.
24 October 2025
Johnson & Johnson: Nipocalimab Reduces Sjögren’s Disease Activity and Severity
Nipocalimab shows promise in reducing Sjögren’s disease symptoms and autoantibodies, with a favorable safety profile and ongoing Phase 3 trials.
24 October 2025
Merus Reports Positive Interim Data on Petosemtamab in Metastatic Colorectal Cancer
Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
24 October 2025
Johnson & Johnson's Icotrokinra Shows Promising Long-Term Results for Scalp and Genital Psoriasis
Icotrokinra achieves high skin clearance rates in difficult psoriasis areas over 52 weeks, maintaining safety and efficacy in both adults and adolescents.
24 October 2025
Eni Q3 and Nine-Month 2025 Results
Strong Q3 performance with increased cash generation, share buyback, and production growth. Strategic projects in LNG, biorefining, and CCUS advance, maintaining low leverage and stable dividends.
23 October 2025
BASF and ANDRITZ License Agreement for OASE Technology
OASE technology to capture 435,000 tons of CO2 annually in Aarhus waste-to-energy plant, pending Danish CCS fund approval.
23 October 2025
Arkema Advances Decarbonization at Lacq/Mourenx Site
Arkema's TREFLe Project cuts SO2 emissions by 40% and GHG by 10%, producing sulfuric acid for reuse and reducing water use, with €40M investment partly funded by France 2030 plan.
23 October 2025
RWE Begins 92 MW Onshore Wind Projects in Italy
RWE starts building two wind farms in Italy, totaling 92 MW, to power over 83,000 homes. Completion is set for late 2026.
23 October 2025
NEXTCHEM Secures Engineering Contract with newcleo for Modular Nuclear Plant Design
NEXT-N to design a nuclear plant's conventional island, leveraging MAIRE's expertise, aiming for carbon-neutral chemistry with hydrogen and ammonia integration.
23 October 2025
INEOS Alerts Europe on Risk to Medicine Supply
European BDO production is threatened by cheap imports from China, risking jobs and medicine supply chains. Urgent EU action is needed to block unfair competition and protect local industry.
22 October 2025
Boehringer Ingelheim's JASCAYD® Approved in China for IPF Treatment
Nerandomilast, approved in China for IPF, showed significant lung function improvement in Phase III trials. It offers favorable tolerability and is also FDA-approved in the U.S.
22 October 2025
Equinor Q3 2025 Safety Report
A fatal accident occurred at Mongstad. Safety metrics improved, with reduced incident and injury frequencies. Focus on preventive measures and supplier collaboration continues.
22 October 2025
EU Report Highlights Growth in Sustainable Aviation Fuel
EASA's report shows increased SAF production in the EU, with biofuels dominating. A 2030 target of 6% SAF blending is on track, but synthetic fuels are still developing.
21 October 2025
Veolia to Operate Chile's First Desalination Plant in Valparaíso
Veolia wins a four-year contract to manage a desalination plant and aqueduct in Chile, focusing on renewable energy and local labor, with potential extensions until 2040.
← Previous
Next →
